Plerixafor used in a “just in time” fashion allows timely autologous hematopoietic cell transplant (HCT) in patients who are at high risk for inadequate apheresis

Category Primary study
JournalBiology of Blood and Marrow Transplantation
Year 2016
This article has no abstract
Epistemonikos ID: 4ed864a4b192ae5bf113ca25cff3c5755f11e230
First added on: Feb 07, 2025